Retrospective analysis of autoimmune hepatitis-primary biliary cirrhosis overlap syndrome in Korea: characteristics, treatments, and outcomes.
10.3350/cmh.2015.21.2.150
- Author:
Yoonsang PARK
1
;
Yuri CHO
;
Eun Ju CHO
;
Yoon Jun KIM
Author Information
1. Department of Internal Medicine and Liver Research institute, Seoul National University College of Medicine, Seoul, Korea. yoonjun@snu.ac.kr
- Publication Type:Original Article
- Keywords:
Autoimmune hepatitis;
Primary biliary cirrhosis;
Overlap syndrome
- MeSH:
Adult;
Aged;
Cohort Studies;
Drug Therapy, Combination;
Female;
Hepatitis, Autoimmune/complications/*diagnosis;
Humans;
Liver/metabolism/pathology;
Liver Cirrhosis, Biliary/complications/*diagnosis/drug therapy;
Male;
Middle Aged;
Republic of Korea;
Retrospective Studies;
Steroids/therapeutic use;
Treatment Outcome;
Ursodeoxycholic Acid/therapeutic use
- From:Clinical and Molecular Hepatology
2015;21(2):150-157
- CountryRepublic of Korea
- Language:English
-
Abstract:
BACKGROUND/AIMS: Overlap syndrome of autoimmune hepatitis (AIH) and primary biliary cirrhosis (PBC) (AIH-PBC overlap syndrome) is a rare disease that has not been clearly characterized in Korean patients. This study investigated the clinical features of AIH-PBC overlap syndrome compared with those of AIH and PBC alone. METHODS: This retrospective cohort study included 158 consecutive patients who were diagnosed as AIH (n=61), PBC (n=81), or AIH-PBC overlap syndrome (n=9) based on the Paris and the International Autoimmune Hepatitis Group (IAIHG) criteria from 2001 to 2011 in Korea. We compared the clinical features of these three groups retrospectively, including their biochemical characteristics, treatments, responses, and clinical outcomes. RESULTS: The AIH-PBC overlap syndrome patients exhibited biochemical characteristics of both AIH and PBC, and showed a similar response to ursodeoxycholic acid (UDCA) monotherapy as for the PBC patients. However, the response of AIH-PBC overlap syndrome patients to UDCA and steroid combination therapy was worse than the response of AIH patients to steroid-based therapy (P=0.024). Liver cirrhosis developed more rapidly in AIH-PBC overlap syndrome patients than in AIH patients group (P=0.013), but there was no difference between AIH-PBC overlap syndrome patients and PBC patients. The rates of developing hepatic decompensation did not differ significantly between the groups. CONCLUSIONS: The AIH-PBC overlap syndrome patients exhibited a worse response to UDCA and steroid combination therapy and a faster cirrhotic progression compared with AIH patients.
